DarioHealth Corp. (DRIO) News
Filter DRIO News Items
DRIO News Results
|Loading, please wait...|
DRIO News Highlights
- For DRIO, its 30 day story count is now at 4.
- Over the past 28 days, the trend for DRIO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest DRIO News From Around the Web
Below are the latest news stories about DARIOHEALTH CORP that investors may wish to consider to help them evaluate DRIO as an investment opportunity.
DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, today announced preliminary unaudited revenue results for the fourth quarter and full year 2022 of approximately $6.7 million and approximately $27.5 million, respectively. Expected fourth quarter revenue shows a consecutive quarter increase relative to the third quarter of 2022 ($6.6 million) which in turn was higher than the second quarter of 2022 ($6.2 million). Fourth quarte
DarioHealth rallied off a low in December and since raced to new highs. Read why we advocate a Hold rating on DRIO stock.
DarioHealth Corp. (NASDAQ: DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced today the hire of seasoned industry sales leader Matt Alberico as Senior Vice President of Growth to help the Company capitalize on its rapidly growing opportunities across multiple market segments.
Dario Publishes New Research in Peer Reviewed Journal Demonstrating Improved Outcomes by Race and Ethnicity
DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, announced today the publication of new research in the peer-reviewed journal Applied Sciences demonstrating improved outcomes for users living with diabetes across different racial and ethnic groups. The research appears in the journal as part of the Special Issue: Digital Therapeutics Applications for Chronic Disease Management.
Institutions profited after DarioHealth Corp.'s (NASDAQ:DRIO) market cap rose US$29m last week butindividual investors profited the most
A look at the shareholders of DarioHealth Corp. ( NASDAQ:DRIO ) can tell us which group is most powerful. And the group...
In 2023, the only certainty will be uncertainty.
DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, announced today that a large Northeast U.S. supermarket chain (the "Employer") selected Dario to help improve the cardiometabolic health of its employees beginning in the first quarter of 2023, marking the Company reaching 100 enterprise contracts signed. This milestone achievement validates the Company's strategic position as a leading provider of integrated digital chronic con
DarioHealth Corp. (NASDAQ:DRIO) Q3 2022 Earnings Call Transcript November 15, 2022 DarioHealth Corp. beats earnings expectations. Reported EPS is $-0.64, expectations were $-0.76. Operator: Good day, everyone, and welcome to the DarioHealth Third Quarter 2022 Results Conference Call. Please note, this event is being recorded. I would now like to turn the conference over to […]
Leading International Wellness Company Selects Dario as Partner for Musculoskeletal Health Improvement Program
DarioHealth Corp. (NASDAQ: DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced today a new partnership with ECES, a leading international wellness company, to deploy Dario Move throughout Greece and Cyprus as part of a planned government sponsored initiative. The program will launch in early 2023 with a mandate to screen a minimum of 50,000 citizens in support of improving musculoskeletal health of the Greek and Cyprus populations.
EQS-News: DarioHealth Corp. (NASDAQ: DRIO) Prominently Positioned for Digital Therapeutics Consolidation
EQS-News: RazorPitch/DRIO DarioHealth Corp. (NASDAQ: DRIO) Prominently Positioned for Digital Therapeutics Consolidation 21.12.2022 / 11:00 CET/CEST The issuer is solely responsible for the content of this announcement. Article Highlights Transition to valued-based